Insider Selling: Amphastar Pharmaceuticals Inc (AMPH) Insider Sells 16,630 Shares of Stock
Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) insider Jason B. Shandell sold 16,630 shares of the company’s stock in a transaction that occurred on Monday, December 3rd. The stock was sold at an average price of $22.44, for a total value of $373,177.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Shares of NASDAQ:AMPH opened at $21.99 on Friday. Amphastar Pharmaceuticals Inc has a 1 year low of $14.40 and a 1 year high of $22.74. The company has a market cap of $1.00 billion, a PE ratio of 108.60 and a beta of 1.42. The company has a debt-to-equity ratio of 0.10, a quick ratio of 1.34 and a current ratio of 2.02.
Amphastar Pharmaceuticals (NASDAQ:AMPH) last announced its earnings results on Thursday, November 8th. The company reported $0.12 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.11 by $0.01. Amphastar Pharmaceuticals had a positive return on equity of 2.80% and a negative net margin of 2.33%. The firm had revenue of $75.54 million for the quarter, compared to analyst estimates of $76.84 million. During the same quarter last year, the firm posted $0.07 EPS. The business’s revenue was up 30.5% on a year-over-year basis. Sell-side analysts expect that Amphastar Pharmaceuticals Inc will post -0.06 EPS for the current fiscal year.
Several equities research analysts have commented on AMPH shares. Needham & Company LLC set a $25.00 price objective on Amphastar Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, November 9th. Wells Fargo & Co restated a “buy” rating on shares of Amphastar Pharmaceuticals in a research report on Friday, November 9th. Jefferies Financial Group restated a “buy” rating and issued a $26.00 price objective on shares of Amphastar Pharmaceuticals in a research report on Wednesday, November 14th. BidaskClub lowered Amphastar Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Thursday, September 13th. Finally, ValuEngine upgraded Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, August 17th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $23.60.
Amphastar Pharmaceuticals Company Profile
Amphastar Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and internationally. It operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients.
Further Reading: What is a Candlestick Chart?
Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.